What is HC Wainwright’s Estimate for Insmed Q3 Earnings?

Insmed, Inc. (NASDAQ:INSM) – Investment analysts at HC Wainwright issued their Q3 2026 EPS estimates for shares of Insmed in a research note issued to investors on Monday, February 23rd. HC Wainwright analyst A. Fein expects that the biopharmaceutical company will earn ($0.98) per share for the quarter. HC Wainwright has a “Buy” rating and a $230.00 price target on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q4 2026 earnings at $0.18 EPS, FY2026 earnings at ($2.92) EPS, FY2027 earnings at $0.78 EPS and FY2030 earnings at $10.17 EPS.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The firm had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. Insmed’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.32) EPS.

INSM has been the topic of a number of other reports. Leerink Partners reissued an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Barclays began coverage on Insmed in a research report on Tuesday, January 27th. They set an “overweight” rating and a $231.00 target price for the company. Guggenheim decreased their target price on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Rothschild & Co Redburn set a $263.00 price target on Insmed in a research note on Thursday, December 4th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Insmed has an average rating of “Buy” and a consensus target price of $207.52.

Insmed Stock Down 6.3%

Shares of INSM stock opened at $148.61 on Wednesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. Insmed has a one year low of $60.40 and a one year high of $212.75. The company’s fifty day moving average price is $162.53 and its 200-day moving average price is $164.47. The company has a market capitalization of $32.03 billion, a price-to-earnings ratio of -23.18 and a beta of 1.11.

Insider Buying and Selling at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of Insmed stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the transaction, the insider directly owned 41,754 shares of the company’s stock, valued at $7,315,300.80. This trade represents a 67.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO William Lewis sold 19,215 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer owned 306,891 shares in the company, valued at $51,864,579. This represents a 5.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 178,952 shares of company stock valued at $30,222,170 in the last quarter. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. CoreCap Advisors LLC bought a new stake in Insmed in the fourth quarter worth about $27,000. GraniteShares Advisors LLC purchased a new stake in shares of Insmed in the fourth quarter worth approximately $30,000. CIBC Private Wealth Group LLC lifted its stake in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares during the last quarter. Raiffeisen Bank International AG purchased a new position in Insmed during the 4th quarter valued at $32,000. Finally, Stone House Investment Management LLC bought a new position in Insmed in the 3rd quarter valued at $29,000.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: UK regulator granted marketing authorization for brensocatib (brensocatib approval expands EU/UK commercialization opportunity for a late-stage asset). Article Title
• Positive Sentiment: Insmed reported BRINSUPRI sales that beat expectations and set a 2026 sales target — evidence of improving commercial traction for its lead product, which supports longer‑term revenue upside. Article Title
• Positive Sentiment: Asset/strategy recognition from investors: mutual‑fund commentary highlighted ARIKAYCE as a driver for performance, lending third‑party validation of the commercial story. Article Title
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and a $230 price target, which is bullish versus the current price and signals continued analyst confidence in the long‑term story. Article Title
• Neutral Sentiment: HC Wainwright issued a broad set of updated forecasts across 2026–2030 (mix of near‑term cuts and long‑term increases) — the firm lowered FY2026/FY2028/FY2029 estimates but raised FY2027 and issued a bullish FY2030 projection ($10.17 EPS). These revisions show diverging near‑term pressure and stronger long‑term growth expectations. Article Title
• Negative Sentiment: HC Wainwright trimmed several near‑term EPS estimates (Q1–Q3 2026 and FY2026) — lower short‑term profit expectations can pressure the stock while the market re‑prices growth timing. Article Title
• Negative Sentiment: Insider selling: CEO William Lewis has executed several stock sales recently (most recently ~10.7k shares for ~$1.6M), which investors often interpret as a negative signal even if sales are routine or for diversification. Article Title
• Negative Sentiment: Mizuho trimmed its price target from $211 to $204 (still an Outperform) — a modest signal that some analysts are tempering near‑term expectations. Article Title

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.